The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists-including medications such as Ozempic, Wegovy, and Mounjaro-has fundamentally altered the clinical approach to obesity and type 2 diabetes. Originally approved to improve glycemic control, these drugs are now at the center of a fast-growing weight loss market, reshaping benefit design for employers, insurers, and public payers. While these therapies have demonstrated significant efficacy in weight reduction, new data suggests a concerning trend: patients initiating these medications may experience a decline in physical activity, challenging the assumption that weight loss automatically translates into a more active, healthier lifestyle.
The Activity Paradox in Pharmacological Weight Loss
Research presented at ENDO 2026 indicates that rather than acting as a catalyst for increased movement, GLP-1 medications are associated with a decrease in both daily step counts and moderate-to-vigorous physical activity (MVPA). This suggests a disconnect between the physiological achievement of weight loss and the behavioral adoption of exercise, even as clinical guidelines continue to emphasize lifestyle change as a core component of obesity care.
“While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise,” stated Sajana Maharjan, MD, board-certified internist at HSHS St. John’s Hospital in Springfield, IL, and lead author of the study.
The study analyzed 753 participants with obesity who utilized Fitbit devices to track activity before and after starting GLP-1 therapy. The cohort was predominantly female (78.6%) with an average age of 52.7. The resulting data revealed a measurable dip in movement across the group:
| Metric | Pre-Medication Average | Post-Medication Average |
|---|---|---|
| Daily Step Count | 5,047 | 4,487 |
| Moderate-to-Vigorous Activity (MVPA) | 28 minutes/day | 22 minutes/day |
The most pronounced declines were not uniform across the population. Males and individuals reporting musculoskeletal pain showed the greatest reduction in activity levels. Conversely, factors such as heart failure, previous stroke, or age did not significantly alter these trends, suggesting that the activity drop-off may be driven more by behavior and tolerability than by underlying cardiovascular risk alone.
Clinical Risks of Reduced Mobility
From a public health perspective, weight loss achieved through medication without concurrent physical activity presents a risk to long-term metabolic health. The primary concern for clinicians is the preservation of lean muscle mass. Rapid weight loss often involves a combination of fat loss and muscle atrophy, which can lead to increased frailty, poorer balance, and a slower basal metabolic rate-especially in middle-aged and older adults who already face age-related muscle decline.
Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center, noted that a lack of exercise can “lead to increased muscle loss, heightened fatigue, and suboptimal weight loss results.”
Fatigue is a frequently reported side effect of GLP-1 medications, which can create a feedback loop that discourages exertion. “This study aligns with my clinical experience. I often find that patients feel more fatigued while losing weight, which can make exercise feel like a chore,” Ali noted. For systems already grappling with rising rates of cardiometabolic disease, that pattern raises questions about how these drugs are prescribed, monitored, and supported in real-world practice.
Systemic and Policy Implications for Obesity Management
The findings underscore a critical need for a shift in healthcare delivery. The current trend toward “prescription-only” weight loss-where a GLP-1 script may be issued via telehealth or retail clinics with limited follow-up-may overlook the necessary infrastructure of integrated care. Payers and health systems are investing billions of dollars in GLP-1 coverage; without built-in requirements or incentives for lifestyle support, those investments risk delivering narrower health benefits than anticipated.
To ensure sustainable outcomes, the medical community is under increasing pressure from regulators and professional bodies to transition from a focus on weight reduction to a focus on overall body composition and functional capacity. In the United States, the Food and Drug Administration, which oversees the labeling and approved indications of GLP-1 receptor agonists, has consistently required that anti-obesity drugs be used as an adjunct to a reduced-calorie diet and increased physical activity, not as a stand-alone solution. That regulatory framing, available through the Food and Drug Administration’s drug safety and approvals portal, now sits in tension with consumer expectations of a “shortcut” to better health.
Integrating physical activity guidelines into the prescription protocol is essential for mitigating the risks of muscle loss. Maharjan emphasized that “the findings in our study reinforce that exercise cannot be optional for people taking these medications. People need targeted interventions that encourage physical activity alongside medication for obesity.” For clinicians and policymakers, that may mean tying coverage of GLP-1s to participation in structured lifestyle programs, employer wellness initiatives, or digital coaching that tracks both medication use and movement.
For those managing the side effects of these therapies, clinical perspectives suggest that the approach to movement should be adaptable, particularly for patients with joint pain or low baseline fitness. Ali noted that “consistency is more important than intensity.”
- Recommended Frequency: Aim for at least 30 minutes of physical activity per day, five days a week.
- Adaptability: Activity can be broken into smaller segments-such as three 10-minute walks-if a continuous 30-minute block is not feasible.
- Modality: A combination of aerobic exercise and resistance training is optimal for preserving muscle and supporting metabolic health.
- Primary Goal: Even low-impact movements, such as walking or chair-based exercises, provide meaningful benefits when performed regularly.
Ultimately, while GLP-1s provide a powerful tool for systemic health improvement and are rapidly becoming embedded in employer benefits, Medicare debates, and national obesity strategies, they are not a replacement for the physiological and functional benefits of movement. “While the majority of weight loss stems from dietary changes, physical activity remains essential for muscle preservation and overall health,” Ali concluded. For health systems and policymakers, the emerging evidence from ENDO 2026 is a reminder that drug innovation, on its own, cannot substitute for building environments, benefits, and clinical pathways that make daily movement achievable for the millions now turning to GLP-1s.
Keep reading
